Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 491.135 USD -1.08%
Market Cap: 126.8B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is 265.569 USD. Compared to the current market price of 491.135 USD, Vertex Pharmaceuticals Inc is Overvalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
Base Case
265.569 USD
Overvaluation 46%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
41
Median 3Y
9.3
Median 5Y
9.5
Industry
8.1
Forward
11.4
vs History
vs Industry
6
Median 3Y
25
Median 5Y
25.6
Industry
23
Forward
1 207.2
vs History
vs Industry
6
Median 3Y
21.1
Median 5Y
22.1
Industry
23.4
vs History
vs Industry
5
Median 3Y
23.1
Median 5Y
24.1
Industry
27.3
vs History
25
vs Industry
12
Median 3Y
5.9
Median 5Y
6.3
Industry
2.6
vs History
19
vs Industry
36
Median 3Y
8.2
Median 5Y
8.4
Industry
8.1
Forward
10.9
vs History
19
vs Industry
31
Median 3Y
9.3
Median 5Y
9.6
Industry
9.6
vs History
22
vs Industry
4
Median 3Y
19.4
Median 5Y
19.4
Industry
4.3
Forward
90.4
vs History
22
vs Industry
4
Median 3Y
20.1
Median 5Y
20.4
Industry
3.8
Forward
198.2
vs History
vs Industry
5
Median 3Y
18.5
Median 5Y
19.4
Industry
6
vs History
vs Industry
5
Median 3Y
19.9
Median 5Y
20.6
Industry
3.8
vs History
42
vs Industry
23
Median 3Y
9.1
Median 5Y
9.7
Industry
4.8

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 11.9 -263.9 26.7 28
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
300.2B USD 5.4 59 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 4.9 37.4 17.5 33.2
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 4.1 910.1 10.1 10.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
137.3B AUD 6 33.7 20.8 25.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 6.3 18.8 17.3 19.2
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
33.8B USD 16.1 -101.7 -244.6 -170.3
P/E Multiple
Earnings Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 211.8
Negative Multiple: -263.9
42%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -101.7 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 17.9
26.7
38%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -244.6 N/A
EV/EBIT Multiple
EBIT Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 23.2
28
44%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.2
93%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
25.9
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.2
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -170.3 N/A

See Also

Discover More
Back to Top